Please login to the form below

Not currently logged in
Email:
Password:

Swiss biotech Inositec appoints new chief medical officer

Dr Frits van Alphen joins the group from Roche

Zurich-based biotechnology company Inositec has appointed a new chief medical officer in the form of Dr Frits van Alphen.

He said: “As CMO of Inositec, I have the golden opportunity to utilise my broad experience and entrepreneurial mind-set to develop new medicines.

“These innovative products have the potential to significantly advance patient care in vascular and other calcification disorders, all with high unmet medical need.”

Dr van Alphen joins from Roche, where he headed its operational excellence team and prior to this he was chief medical officer at Vifor Pharma, head of medical affairs Europe at Novartis as well as heading their clinical operations team in the Netherlands.

Dr Mattias Ivarsson, chief medical officer of Inositec, said: “Dr van Alphen is a key addition to Inositec’s team as we enter IND/CTA-enabling studies with out lead programme in the vascular calcification space and fine-tune our clinical strategy in view of first-in-human studies in 2019.”

23rd January 2018

From: Research

Share

Tags

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
Create Health

A specialist Advertising and Med Comms agency dedicated to bringing much-needed creativity to healthcare marketing. We believe that brilliant ideas...

Latest intelligence

Value is in the eye of the customer. Co-creation is a bridge to value.
We conducted 16 hours of qualitative interviews with HCPs and Senior Pharma industry leaders in the UK, supported with in-depth industry scanning. Our interviews reveal important insights about the tensions...
Partnering with Patients and Caregivers in Clinical Research
...
Practical advice for Early Scientific Advice (ESA) in HTA submissions
A step-by step guide on the benefits, processes, and key considerations involved in the Healthcare Technology Assessment (HTA) Early Scientific Advice (ESA) consultation as part of planning the holistic evidence...